Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Nov 03, 2017

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer

  • The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

Tocagen’s combo therapy enters directly into phase 3 trials after getting approval from FDA

  • Tocagen is moving directly into a phase 3 trial with its combo therapy Toca 511 and Toca FC gene therapy in cancer and thus needs more patients. To facilitate the process FDA has provided a $2 million orphan drug grant payable over four years.

FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure

  • Under the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud. The agency has recently issued warning letters to four companies. Action is taken against the companies illegally selling marijuana products online claiming to prevent, diagnose, treat, or cure cancer without any evidence to support the same.

FDA about to Revoke Claims regarding Heart Health benefits of Soy

  • In a recent statement Susan Mayne, director of the Center for Food Safety and Applied Nutrition at the FDA has said that, the relationship between soy protein and heart health does not meet the rigorous standard for an FDA-authorized health claim.

Downloads

Article in PDF

Recent Articles
  1. Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares f...
  2. Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches
  3. Notizia
  4. Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016
  5. Merck’s Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women’s...
medtech-news-of-cartessa-logicmark-boston-scientific
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Cartessa Aesthetics teams with Classys for Everesse; LogicMark unveils Freedom Alert Max; GE HealthCare clears SIGNA MAGNUS MRI; OMRON’s BP monitor with AI-powered AFib detection gets FDA approval; Boston Scientific’s WATCHMAN FLX™ cuts bleeding risk; Encora Therapeutics wraps ULTRE trial for tremor device

pharma-news-for-regeneron-astrazeneca-syndax
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves PTC’s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia

cell-and-gene-therapy-for-parkinsons-disease-treatment
Articles

The Future of Parkinson’s Disease Treatment: Unlocking the Potential of Cell and Gene Therapy

AstraZeneca
business research
Cancer
Cancer Treatment
CRT
DelveInsight
Early Lung Cancer
FDA
Gene therapy
heart health
Incyte
marijuana
Market Research
NSCLC
orphan drug grant
pharma news
pharmaceutical
Phase 3
soy protein
Susan Mayne
Toca 511
Toca FC
Tocagen
unresectable non-small cell lung cancer
loader